Delivery of beta-blockers through an inhalation route
First Claim
1. A method of treating hypertension, acute myocardial infarction, cardiac arrhythmias or side effects of situational anxiety comprising administering a therapeutic amount of an atenolol, pindolol, esmolol, propranolol, or metoprolol condensation aerosol, having an MMAD less than 3 μ
- m and less than 5% atenolol, pindolol, esmolol, propranolol, or metoprolol degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to the delivery of atenolol, pindolol, esmolol, propranolol, or metoprolol through an inhalation route. Specifically, it relates to aerosols containing atenolol, pindolol, esmolol, propranolol, or metoprolol that are used in inhalation therapy. In a method aspect of the present invention, atenolol, pindolol, esmolol, propranolol, or metoprolol is administered to a patient through an inhalation route. The method comprises: a) heating a composition of atenolol, pindolol, esmolol, propranolol, or metoprolol, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles with less than 5% drug degradation products. In a kit aspect of the present invention, a kit for delivering atenolol, pindolol, esmolol, propranolol, or metoprolol through an inhalation route is provided which comprises: a) a thin coating of an atenolol, pindolol, esmolol, propranolol, or metoprolol composition and b) a device for dispensing said thin coating as a condensation aerosol.
94 Citations
20 Claims
-
1. A method of treating hypertension, acute myocardial infarction, cardiac arrhythmias or side effects of situational anxiety comprising administering a therapeutic amount of an atenolol, pindolol, esmolol, propranolol, or metoprolol condensation aerosol, having an MMAD less than 3 μ
- m and less than 5% atenolol, pindolol, esmolol, propranolol, or metoprolol degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
- 11. A method of administering atenolol, pindolol, esmolol, propranolol, or metoprolol to a patient to achieve a peak plasma drug concentration rapidly, comprising administering to the patient by inhalation an aerosol of atenolol, pindolol, esmolol, propranolol, or metoprolol having less than 5% atenolol, pindolol, esmolol, propranolol, or metoprolol degradation products and an MMAD less than 3 microns wherein the peak plasma drug concentration is achieved in less than 0.1 hours.
-
12. A kit for delivering a drug aerosol comprising:
-
a) a thin coating of an atenolol, pindolol, esmolol, propranolol, or metoprolol composition, and b) a device for dispensing said thin coating as a condensation aerosol. - View Dependent Claims (13, 14, 15, 16, 17, 18, 19)
-
Specification